Get the Stockscreener App
73.31
0.83%
-0.61
Pre-market:
71.00
-2.31
-3.15%
Ani Pharmaceuticals Inc stock is traded at $73.31, with a volume of 219.70K.
It is down -0.83% in the last 24 hours and down -4.42% over the past month.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
See More
Previous Close:
$73.92
Open:
$73.19
24h Volume:
219.70K
Relative Volume:
0.50
Market Cap:
$1.64B
Revenue:
$883.37M
Net Income/Loss:
$71.37M
P/E Ratio:
21.87
EPS:
3.3516
Net Cash Flow:
$150.90M
1W Performance:
-1.31%
1M Performance:
-4.42%
6M Performance:
-22.82%
1Y Performance:
+11.11%
1-Day Range:
$72.82
$74.43
1-Week Range:
$72.20
$76.00
52-Week Range:
$56.71
$99.50
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
Name
Ani Pharmaceuticals Inc
Sector
Phone
(218) 634-3500
Address
210 MAIN STREET WEST, BAUDETTE, MN
Compare ANIP vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANIP
Ani Pharmaceuticals Inc
|
73.31 | 1.64B | 883.37M | 71.37M | 150.90M | 3.3516 |
TAK
Takeda Pharmaceutical Co Adr
|
18.04 | 56.99B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
115.93 | 48.94B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.30B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.14 | 33.94B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
531.82 | 23.31B | 3.18B | 1.33B | 1.04B | 27.90 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Initiated | H.C. Wainwright | Buy |
| Mar-14-25 | Initiated | Jefferies | Buy |
| Mar-12-25 | Initiated | JP Morgan | Overweight |
| Dec-11-24 | Initiated | Leerink Partners | Outperform |
| Oct-11-24 | Initiated | Piper Sandler | Overweight |
| Mar-15-24 | Initiated | CapitalOne | Overweight |
| Aug-22-23 | Reiterated | H.C. Wainwright | Buy |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Sep-07-22 | Initiated | H.C. Wainwright | Buy |
| Nov-02-21 | Initiated | Truist | Buy |
| May-07-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-12-19 | Initiated | Guggenheim | Buy |
| May-10-19 | Downgrade | Raymond James | Strong Buy → Outperform |
| Oct-16-17 | Reiterated | Canaccord Genuity | Buy |
| Jul-31-17 | Initiated | Canaccord Genuity | Buy |
| Feb-22-17 | Downgrade | ROTH Capital | Buy → Neutral |
| Jun-23-16 | Initiated | Raymond James | Strong Buy |
| May-24-16 | Downgrade | Standpoint Research | Buy → Hold |
| Nov-13-15 | Initiated | Standpoint Research | Buy |
| Sep-28-15 | Upgrade | ROTH Capital | Neutral → Buy |
| Aug-05-15 | Reiterated | Oppenheimer | Outperform |
| Aug-04-15 | Reiterated | ROTH Capital | Neutral |
| Jul-31-15 | Reiterated | Oppenheimer | Outperform |
| Jul-15-15 | Reiterated | ROTH Capital | Neutral |
| Jun-23-15 | Reiterated | Oppenheimer | Outperform |
| May-18-15 | Reiterated | ROTH Capital | Neutral |
| May-06-15 | Reiterated | Oppenheimer | Outperform |
| Apr-10-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Feb-26-15 | Reiterated | ROTH Capital | Buy |
| Feb-18-15 | Reiterated | Oppenheimer | Outperform |
View All
Ani Pharmaceuticals Inc Stock (ANIP) Latest News
INSM Stock Gains After Arikayce Hits Goal in Label Expansion Study - TradingView
Oliver Luxxe Assets LLC Invests $1.82 Million in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
BioSante Pharmaceuticals and ANI Pharmaceuticals Announce Completion of Merger - Yahoo
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
ANI Pharmaceuticals Expands Ophthalmology Reach As Valuation Signals Upside Potential - Yahoo Finance
Assessing ANI Pharmaceuticals (ANIP) Valuation After Rare Disease Momentum And Alimera Acquisition - Sahm
Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why - TradingView
Agios Pharmaceuticals Stock Declines 23% in 6 Months: Here's Why - TradingView
Guggenheim Remains a Buy on ANI Pharmaceuticals (ANIP) - The Globe and Mail
ANIP Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Is ANI Pharmaceuticals (ANIP) Pullback Hiding A Contradiction In Its Valuation Story - simplywall.st
EPS Watch: Can ANI Pharmaceuticals Inc lead its sector in growthQuarterly Earnings Summary & Fast Entry Momentum Alerts - baoquankhu1.vn
COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM - TradingView
ANIP PE Ratio & Valuation, Is ANIP Overvalued - Intellectia AI
IBRX Stock Jumps on Progress in NK Cell Therapy Production - TradingView
Zacks Industry Outlook Features Terns Pharmaceuticals, ADMA Biologics, ANI Pharmaceuticals, and Liquidia - Bitget
Zacks Industry Outlook Highlights Terns Pharmaceuticals, ADMA Biologics, ANI Pharmaceuticals and Liquidia - The Globe and Mail
ANI Pharmaceuticals Insiders Unload $584K in Shares Amid 18-Month Selling Streak - AlphaStreet
234,219 Shares in ANI Pharmaceuticals, Inc. $ANIP Acquired by Divisadero Street Capital Management LP - MarketBeat
Apis Capital Advisors LLC Purchases 36,000 Shares of ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Form 4 ANI Pharmaceuticals Inc For: 13 March By Investing.com - Investing.com Australia
ANI Pharmaceuticals (NASDAQ:ANIP) Stock Rating Lowered by Wall Street Zen - MarketBeat
Ani Pharmaceuticals SVP Cook sells $36k in stock - Investing.com
Ani Pharmaceuticals SVP Cook sells $36k in stock By Investing.com - Investing.com South Africa
Meredith Cook Sells 500 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock - MarketBeat
Insider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) Insider Sells 3,162 Shares of Stock - MarketBeat
ANI Pharmaceuticals (NASDAQ:ANIP) SVP Thomas Andrew Rowland Sells 4,772 Shares - MarketBeat
Ani pharmaceuticals SVP Rowland sells $357k in stock By Investing.com - Investing.com South Africa
Ani pharmaceuticals SVP Rowland sells $357k in stock - Investing.com
[Form 4] ANI PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
ANI Pharmaceuticals (ANIP) legal chief sells 500 shares under 10b5-1 plan - Stock Titan
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q4 - TradingView
ANI Pharmaceuticals, Inc. $ANIP Stock Position Reduced by Kennedy Capital Management LLC - MarketBeat
Sizing Up ANI Pharmaceuticals (ANIP) After Recent Share Price Pullback - Yahoo Finance
Pharma Sector Q1 2026 Earnings Review: Mixed Results & Future OutlookNews and Statistics - IndexBox
How ANI’s Reaffirmed 2026 Guidance and Rare Disease Push Will Impact ANI Pharmaceuticals (ANIP) Investors - simplywall.st
Beam Therapeutics Stock Surges 23% in 6 Months: What's Driving It? - TradingView
ANIP SEC FilingsAni Pharmaceutic 10-K, 10-Q, 8-K Forms - Stock Titan
ANI Pharmaceuticals touts rare-disease pivot at Barclays, guides 2026 revenue above $1B - MarketBeat
ANI Pharmaceuticals at Barclays Conference: Rare Disease Focus Drives Growth - Investing.com Canada
Mineralys Stock Rises as FDA Accepts NDA for Hypertension Drug - TradingView
ANI Pharmaceuticals Targets $1.1B 2026 Revenue as Cortrophin Sales Surge, Gout Launch Set for Midyear - MarketBeat
Insider Sell: Krista Davis Sells Shares of ANI Pharmaceuticals I - GuruFocus
ANI Pharmaceuticals (NASDAQ: ANIP) executive sells shares, withholds stock for taxes - Stock Titan
ANI Pharmaceuticals (ANIP) CEO stock withheld to cover taxes - Stock Titan
ANI Pharmaceuticals (ANIP) HR chief sells 6,572 shares under 10b5-1 plan - Stock Titan
GSK Out-Licenses Rights for Rare Liver Disease Drug to Alfasigma - Finviz
BMY Advances CELMoD Program With Positive Phase III Results - TradingView
ANIP Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Ani pharmaceuticals head of rare disease sells $30k in stock - Investing.com Nigeria
INCY Wins EC Approval for Label Expansion of Oncology Drug Zynyz - Finviz
Ani Pharmaceuticals Inc Stock (ANIP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
1.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):